September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Modulating Expression of Thioredoxin Interacting Protein Prevents Secondary Damage and Preserves Visual Function In A Model of Ischemia/Reperfusion
Author Affiliations & Notes
  • Azza B. El-Remessy
    Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, United States
    Vision Discovery Institute, Augusta University, Augusta, Georgia, United States
  • Maha Coucha
    Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, United States
    Vision Discovery Institute, Augusta University, Augusta, Georgia, United States
  • Ahmed Y. Shanab
    Clinical and Experimental Therapeutics, University of Georgia, Augusta, Georgia, United States
    Vision Discovery Institute, Augusta University, Augusta, Georgia, United States
  • Almira Vazdarjanova
    Pharmacology & Toxicology, Augusta University, Augusta, Georgia, United States
  • Footnotes
    Commercial Relationships   Azza El-Remessy, None; Maha Coucha, None; Ahmed Shanab, None; Almira Vazdarjanova, None
  • Footnotes
    Support  EY-022408
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4415. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Azza B. El-Remessy, Maha Coucha, Ahmed Y. Shanab, Almira Vazdarjanova; Modulating Expression of Thioredoxin Interacting Protein Prevents Secondary Damage and Preserves Visual Function In A Model of Ischemia/Reperfusion. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4415.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinal neurodegeneration is an early characteristic of several blinding diseases including diabetes, trauma or glaucoma. Neurodegeneration triggers glial activation resulting in inflammation and secondary damage to other retina cell types, which eventually cause visual impairment. Treatments that aimed only at neuroprotection failed clinically. We and others demonstrated the neuroprotective effects of genetic deletion of thioredoxin interacting protein (TXNIP), the negative regulator of the antioxidant thioredoxin system. Here, we examine the impact of TXNIP to the inflammatory secondary damage and visual impairment in a model of ischemic retinopathy.

Methods : Wild type (WT) and TXNIP knockout (TKO) mice underwent ischemia/reperfusion (IR) injury by increasing intraocular pressure for 40 minutes followed by reperfusion. One group of WT mice received TXNIP antisense oligomers (100µg/2µl) 2-days post ischemic injury. TUNEL assay was used to detect apoptotic cells. Real-time PCR and immunohistochemistry was used to detect TXNIP and activation of Muller glial cells. Vascular degeneration was assessed by trypsin digest, and visual function was assessed by visual cue water-maze test that measures time taken to swim to a fixed platform at 3, 6, 9 days post-injury relative to to base line before injury.

Results : After 3 days, IR injury induced TXNIP mRNA expression (2-fold) that localized within Muller cells in WT compared to sham-controls. These effects were associated with retinal neurodegeneration (2.3-fold in TUNEL-positive cells), substantial GFAP-glial activation at 3-days that was sustained to 14-days in WT-IR but not in TKO-IR. After 14-days, secondary damage was evident by significant increase in number of acellular capillaries and visual impairment in IR-WT mice but not in IR-TKO compared to sham-controls. Importantly, administration of TXNIP-ASO (2-days post-I/R injury) delayed the development acellular capillaries and significantly improved visual function by day-9.

Conclusions : Deletion or inhibition of TXNIP expression prevented ischemia-induced glial activation, neuro-vascular degeneration, and improved visual function compared to WT. Targeting TXNIP expression may be a promising and effective approach in the prevention of secondary damage associated with retinal neurodegenerative diseases.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×